EORTC studies activated in 2011 and 2012

EORTC studies activated in 2012

EORTC trial 62092-22092

A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with Retroperitoneal sarcomas (RPS).

Target Accrual: 256 patients
Study Coordinator:

  • Sylvie Bonvalot – Institut Gustave Roussy, Villejuif

EORTC studies activated in 2011

EORTC trial 55102

A phase III Trial of postoperative chemotherapy or no further treatment for patients with stage I-II medium or high risk endometrial cancer.

Target Accrual: 678 patients
Study Coordinator:

  • Frederic Amant – Universitair Ziekenhuis Gasthuisberg, Leuven

    EORTC trial 06083 – HOVON 100 ALL

    Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults. A prospective randomized trial.

    Target Accrual:  – patients
    Study Coordinator:

    • Jean-Pierre Marie – Hopital Saint Antoine AP-HP, Paris

      EORTC trial 26101

      Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.

      Target Accrual: 249 patients
      Study Coordinator:

      • Wolfgang Wick – Universitaets Klinikum Heidelberg – Kopfklinik, Heidelberg

        EORTC trial 58LAE (Late Adverse Events)

        Assessment of the long term outcome of childhood ALL patients enrolled in EORTC CLG trials between 1971 and 1998.

        Target Accrual: 3138 patients
        Study Coordinator:

        • Caroline Piette – Centre Hospitalier Regional De La Citadelle, Liege

          EORTC trial 08092 – MAPPING

          Double blind randomized phase III study of maintenance Pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy.

          Target Accrual:  587 patients
          Study Coordinator:

          • Mary O'Brien – Royal Marsden Hospital, Sutton

            EORTC trial 62091 – TRUSTS

            A phase IIb/III multicenter study comparing the efficacy of Trabectedin administered as a 3-hour or 24 hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma.

            Target Accrual: 370 patients
            Study Coordinator:

            • Binh Bui-Nguyen – Institut Bergonie, Bordeaux

              EORTC trial 58081

              Translational research – observational study for identification of new possible prognostic factors and future therapeutic targets in children with acute lymphoblastic leukemia (ALL).

              Target Accrual: 800 patients
              Study Coordinator:

              • Helene Cave – Hôpital Robert Debre (AP-HP), Paris

                EORTC trial 26091

                Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial.

                Target Accrual: 144 patients
                Study Coordinator:

                • Martin J. Van den Bent – Erasmus University Medical Center, Rotterdam


                  EORTC studies soon to be opened (in regulatory process)

                  EORTC trial 21082

                  Progression free survival (PFS) comparison between suberoylanilide hydroxamic acid (SAHA, Vorinostat TM) in combination with bortezomib (Velcade TM) and SAHA alone in refractory or recurrent advanced CTCL. A randomized study.

                  Target Accrual: 189 patients
                  Study Coordinator:

                  • Pablo Luis Ortiz-Romero – Hospital Universitario, Madrid

                    EORTC trial 22055 – 08053

                    Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement – LUNG-ART.

                    Target Accrual: 700 patients
                    Study Coordinator:

                    • Cecile Le Pechoux – Institut Gustave Roussy, Villejuif

                      EORTC trial 40084-22084

                      A phase III trial evaluating both Erlotinib and Chemoradiation as adjuvant treatment for patients with resected head of pancreas adenocarcinoma.

                      Target Accrual: 950 patients
                      Study Coordinator:

                      • Jean-Luc Van Laethem – Hospital Universitaire Erasme, Brussels

                        EORTC trial 55092

                        Phase IB-II, open label, multicentre feasibility study of Pazopanib in combination with Paclitaxel and Carboplatin in patients with platinum-refractory/resistant ovarian, fallopian tube or peritoneal carcinoma.

                        Target Accrual: 36 patients
                        Study Coordinator:

                        • Ignace Vergote – Universitair Ziekenhuis Gasthuisberg, Leuven

                          EORTC trial 65091 – 06093

                          Empirical versus pre-emptive antifungal therapy in patients with haematological malignancies. A therapeutic open label phase III strategy study of the EORTC Infectious Diseases and Leukemia Groups.

                          Target Accrual: 556 patients
                          Study Coordinator:

                          • Peter Donnelly – Radboud University Nijmegen Medical Centre, Nijmegen

                            EORTC trial 90101 – CREATE

                            Cross-tumoral Phase 2 clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET ("CREATE").

                            Target Accrual: 582 patients
                            Study Coordinator:

                            • Patrick Schoeffski – Universitair Ziekenhuis Gasthuisberg, Leuven

                              John Bean

                              Back to news list